Cargando…

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury

AIM: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. METHODS: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Asakawa, Masahiro, Mitsui, Hiroshi, Akihisa, Momoko, Sekine, Tetsuo, Niitsu, Yoshihiro, Kobayashi, Arisa, Miyake, Atsuko, Hashimoto, Naoaki, Kawamura, Mitsunobu, Ogawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501339/
https://www.ncbi.nlm.nih.gov/pubmed/26191473
http://dx.doi.org/10.1186/s40064-015-1135-z
_version_ 1782381053740056576
author Asakawa, Masahiro
Mitsui, Hiroshi
Akihisa, Momoko
Sekine, Tetsuo
Niitsu, Yoshihiro
Kobayashi, Arisa
Miyake, Atsuko
Hashimoto, Naoaki
Kawamura, Mitsunobu
Ogawa, Yoshihiro
author_facet Asakawa, Masahiro
Mitsui, Hiroshi
Akihisa, Momoko
Sekine, Tetsuo
Niitsu, Yoshihiro
Kobayashi, Arisa
Miyake, Atsuko
Hashimoto, Naoaki
Kawamura, Mitsunobu
Ogawa, Yoshihiro
author_sort Asakawa, Masahiro
collection PubMed
description AIM: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. METHODS: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated. RESULTS: HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes. CONCLUSION: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis.
format Online
Article
Text
id pubmed-4501339
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-45013392015-07-17 Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury Asakawa, Masahiro Mitsui, Hiroshi Akihisa, Momoko Sekine, Tetsuo Niitsu, Yoshihiro Kobayashi, Arisa Miyake, Atsuko Hashimoto, Naoaki Kawamura, Mitsunobu Ogawa, Yoshihiro Springerplus Research AIM: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. METHODS: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated. RESULTS: HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes. CONCLUSION: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis. Springer International Publishing 2015-07-15 /pmc/articles/PMC4501339/ /pubmed/26191473 http://dx.doi.org/10.1186/s40064-015-1135-z Text en © Asakawa et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Asakawa, Masahiro
Mitsui, Hiroshi
Akihisa, Momoko
Sekine, Tetsuo
Niitsu, Yoshihiro
Kobayashi, Arisa
Miyake, Atsuko
Hashimoto, Naoaki
Kawamura, Mitsunobu
Ogawa, Yoshihiro
Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
title Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
title_full Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
title_fullStr Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
title_full_unstemmed Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
title_short Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
title_sort efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501339/
https://www.ncbi.nlm.nih.gov/pubmed/26191473
http://dx.doi.org/10.1186/s40064-015-1135-z
work_keys_str_mv AT asakawamasahiro efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT mitsuihiroshi efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT akihisamomoko efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT sekinetetsuo efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT niitsuyoshihiro efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT kobayashiarisa efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT miyakeatsuko efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT hashimotonaoaki efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT kawamuramitsunobu efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury
AT ogawayoshihiro efficacyandsafetyofsitagliptinforthetreatmentofdiabetesmellituscomplicatedbychronicliverinjury